#United States #Securities #San Francisco #Berger Montague #Hims & Hers

Investigation into Hims & Hers Health, Inc.

Overview

On June 24, 2025, Berger Montague, a leading firm specializing in securities litigation, announced its investigation into possible legal claims regarding Hims & Hers Health, Inc. (NYSE: HIMS). This inquiry comes in light of Hims & Hers’ substantial decline in stock value, spurred by serious allegations surrounding its practices in the GLP-1 medication market.

Hims & Hers is a telehealth provider based in San Francisco, California, that offers various prescription treatments aimed at weight loss, sexual health, mental health, and dermatological issues. Recently, the company has ventured into the marketing of GLP-1 medications, which include popular drugs like Wegovy® and Ozempic®, formulated by Novo Nordisk to treat obesity and type 2 diabetes.

Background of the Situation

The situation escalated dramatically when Novo Nordisk, the pharmaceutical giant behind the aforementioned medications, announced the termination of its partnership with Hims & Hers on June 23, 2025. Novo Nordisk cited the company’s alleged involvement in deceptive marketing practices and the sale of unapproved compounded versions of semaglutide—the active ingredient in both Wegovy® and Ozempic®.

This announcement resulted in a staggering 26% drop in the value of Hims & Hers shares during intraday trading. Investors reacted swiftly, expressing heightened concerns regarding the company's adherence to regulatory requirements and overall reputational risks.

Investigation Focus

Berger Montague's inquiry aims to determine whether Hims & Hers, alongside certain executives and directors, made materially false or misleading statements or failed to disclose significant information regarding its GLP-1 products. Key areas of concern include:

• - The regulatory status of the medications in question.
• - The potential risks associated with the marketing and sale of these products.
• - Specific details about the partnership with Novo Nordisk and the implications of its termination.

The investigation seeks to uncover whether Hims & Hers misled investors, potentially violating securities laws and regulations.

Call to Action for Investors

Investors who have purchased Hims & Hers securities may have legal options available and are encouraged to reach out for more information. Those interested in understanding their rights and the scope of the investigation can contact Berger Montague directly:

• - Andrew Abramowitz: (215) 875-3015, [email protected]
• - Peter Hamner: [email protected]

Berger Montague has a long-standing reputation in the field of securities class action litigation, having represented both individual and institutional investors for over five decades. The firm operates offices across key U.S. cities, including Philadelphia, Minneapolis, Washington D.C., San Diego, San Francisco, and Chicago.

Conclusion

As developments unfold, understanding the implications of the ongoing investigation is crucial for Hims & Hers investors. The outcome may significantly impact the company's future, not to mention the investments made by its shareholders. Stay informed as Berger Montague continues its investigation into potential securities violations by Hims & Hers Health, Inc.